Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

October 1, 2025

Conditions
DementiaModerate Dementia
Interventions
DRUG

Secretome injection

Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months

DRUG

Vitamin B12 Injection

Patient will receive 1 ampule of vitamin b 12 intramuscular injection as a placebo drug every two weeks for four months

Trial Locations (1)

15431

Panti Werda Hana, Tangeran Selatan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Tarumanagara University

OTHER

collaborator

panti werda hana

UNKNOWN

collaborator

LPPT TARUMANAGARA

UNKNOWN

lead

Baermed

OTHER

NCT06632470 - Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia) | Biotech Hunter | Biotech Hunter